atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_chewing_gum,DDD_implant,DDD_inhale,DDD_inhaleaerosol,DDD_inhalepowder,DDD_N,DDD_O,DDD_P,DDD_R,DDD_SL,DDD_TD,unit_chewing_gum,unit_implant,unit_inhale,unit_inhaleaerosol,unit_inhalepowder,unit_N,unit_O,unit_P,unit_R,unit_SL,unit_TD
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AA,Ethers,No DDDs have been established in this group because the doses used vary substantially.,N01AA01,diethyl ether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AA,Ethers,No DDDs have been established in this group because the doses used vary substantially.,N01AA02,vinyl ether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB01,halothane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB02,chloroform,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB04,enflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB05,trichloroethylene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB06,isoflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB07,desflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB08,sevoflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF01,methohexital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF02,hexobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF03,thiopental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AG,Barbiturates in combination with other drugs,No DDDs have been established in this group because the doses used vary substantially.,N01AG01,narcobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH01,fentanyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH02,alfentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH03,sufentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH04,phenoperidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH05,anileridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH06,remifentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH51,"fentanyl, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX03,ketamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX04,propanidid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX05,alfaxalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX07,etomidate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX10,propofol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX11,sodium oxybate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX13,nitrous oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX14,esketamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX15,xenon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX63,"nitrous oxide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA01,metabutethamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA02,procaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA03,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA04,chloroprocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA05,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA52,"procaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA53,"tetracaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB01,bupivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB02,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB03,mepivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB04,prilocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB05,butanilicaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB06,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB07,etidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB08,articaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB09,ropivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB10,levobupivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB51,"bupivacaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB52,"lidocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB53,"mepivacaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB54,"prilocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB57,"etidocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB58,"articaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB59,bupivacaine and meloxicam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BC,Esters of benzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BC01,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX01,ethyl chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX02,dyclonine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX03,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX04,capsaicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA01,morphine,NA,NA,NA,NA,NA,NA,NA,0.1,30,30,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,mg,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA02,opium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA03,hydromorphone,NA,NA,NA,NA,NA,NA,NA,20,4,4,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA04,nicomorphine,NA,NA,NA,NA,NA,NA,NA,30,30,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA05,oxycodone,NA,NA,NA,NA,NA,NA,NA,75,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA08,dihydrocodeine,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA10,papaveretum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA11,oxymorphone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA51,"morphine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA53,hydromorphone and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA55,oxycodone and naloxone,Refers to oxycodone,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA56,oxycodone and naltrexone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA58,"dihydrocodeine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA59,"codeine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA79,"codeine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB01,ketobemidone,NA,NA,NA,NA,NA,NA,NA,50,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB02,pethidine,NA,NA,NA,NA,NA,NA,NA,0.4,0.4,0.4,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB03,fentanyl,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,0.6,1.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,mg,mg
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB52,"pethidine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB72,"pethidine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC01,dextromoramide,NA,NA,NA,NA,NA,NA,NA,20,20,40,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC03,piritramide,NA,NA,NA,NA,NA,NA,NA,NA,45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC04,dextropropoxyphene,chloride,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC04,dextropropoxyphene,napsylate,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC05,bezitramide,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC52,"methadone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC54,"dextropropoxyphene, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC74,"dextropropoxyphene, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD01,pentazocine,NA,NA,NA,NA,NA,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD02,phenazocine,NA,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD51,pentazocine and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AE,Oripavine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AE01,buprenorphine,NA,NA,NA,NA,NA,NA,NA,NA,1.2,NA,1.2,1.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,mg,mg
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AF,Morphinan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AF01,butorphanol,NA,NA,NA,NA,NA,NA,NA,NA,12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AF,Morphinan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AF02,nalbuphine,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG01,morphine and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG02,ketobemidone and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG03,pethidine and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG04,hydromorphone and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ01,dihydrocodeine and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ02,dihydrocodeine and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ03,dihydrocodeine and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ06,codeine and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ07,codeine and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ08,codeine and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ09,codeine and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ13,tramadol and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ14,tramadol and dexketoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ15,tramadol and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ16,tramadol and celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ17,oxycodone and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ18,oxycodone and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ19,oxycodone and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ22,hydrocodone and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ23,hydrocodone and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX01,tilidine,NA,NA,NA,NA,NA,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX02,tramadol,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX03,dezocine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX05,meptazinol,NA,NA,NA,NA,NA,NA,NA,1.2,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX06,tapentadol,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX07,oliceridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX51,tilidine and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA01,acetylsalicylic acid,Expressed as lysine acetylsalisylate,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA01,acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,3,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA02,aloxiprin,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA03,choline salicylate,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA04,sodium salicylate,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA05,salicylamide,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA06,salsalate,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA07,ethenzamide,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA08,morpholine salicylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA09,dipyrocetyl,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA10,benorilate,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA11,diflunisal,NA,NA,NA,NA,NA,NA,NA,0.75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA12,potassium salicylate,NA,NA,NA,NA,NA,NA,NA,7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA14,guacetisal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA15,carbasalate calcium,NA,NA,NA,NA,NA,NA,NA,3.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA16,imidazole salicylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA51,"acetylsalicylic acid, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA55,"salicylamide, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA57,"ethenzamide, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA59,"dipyrocetyl, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA65,carbasalate calcium combinations excl. psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA67,"magnesium salicylate, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA71,"acetylsalicylic acid, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA75,"salicylamide, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA77,"ethenzamide, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA79,"dipyrocetyl, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB01,phenazone,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB02,metamizole sodium,NA,NA,NA,NA,NA,NA,NA,3,3,3,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB03,aminophenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB04,propyphenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB05,nifenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB51,"phenazone, combinations excl. psycholeptics",Refers to phenazone,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB52,"metamizole sodium, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB53,"aminophenazone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB54,"propyphenazone, combinations excl. psycholeptics",Refers to propyphenazone,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB71,"phenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB72,"metamizole sodium, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB73,"aminophenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB74,"propyphenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE01,paracetamol,NA,NA,NA,NA,NA,NA,NA,3,3,3,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE03,phenacetin,NA,NA,NA,NA,NA,NA,NA,1.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE04,bucetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE05,propacetamol,NA,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE51,"paracetamol, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE53,"phenacetin, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE54,"bucetin, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE71,"paracetamol, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE73,"phenacetin, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE74,"bucetin, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF01,gabapentin,NA,NA,NA,NA,NA,NA,NA,1.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF02,pregabalin,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF03,mirogabalin,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG02,rimazolium,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG03,glafenine,NA,NA,NA,NA,NA,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG04,floctafenine,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG05,viminol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG06,nefopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG07,flupirtine,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG08,ziconotide,NA,NA,NA,NA,NA,NA,NA,NA,12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG09,methoxyflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG10,cannabinoids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG12,tanezumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA01,dihydroergotamine,NA,NA,NA,NA,NA,NA,1,4,4,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA02,ergotamine,NA,NA,NA,NA,4,NA,NA,4,4,4,4,NA,NA,NA,NA,mg,NA,NA,mg,mg,mg,mg,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA04,methysergide,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA07,lisuride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA51,"dihydroergotamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA52,"ergotamine, combinations excl. psycholeptics",Refers to ergotamine,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA72,"ergotamine, combinations with psycholeptics",Refers to ergotamine,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CB,Corticosteroid derivatives,The DDDs for corticosteroid derivatives are based on prophylaxis of migraine.,N02CB01,flumedroxone,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC01,sumatriptan,NA,NA,NA,NA,NA,NA,20,50,6,25,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC02,naratriptan,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC03,zolmitriptan,NA,NA,NA,NA,NA,NA,2.5,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC04,rizatriptan,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC05,almotriptan,NA,NA,NA,NA,NA,NA,NA,12.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC06,eletriptan,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC07,frovatriptan,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC08,lasmiditan,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC51,sumatriptan and naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD01,erenumab,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD02,galcanezumab,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD03,fremanezumab,NA,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD04,ubrogepant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD05,eptinezumab,NA,NA,NA,NA,NA,NA,NA,NA,1.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD06,rimegepant,NA,NA,NA,NA,NA,NA,NA,37.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD07,atogepant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX01,pizotifen,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX02,clonidine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX03,iprazochrome,NA,NA,NA,NA,NA,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX05,dimetotiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX06,oxetorone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA01,methylphenobarbital,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA02,phenobarbital,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA03,primidone,NA,NA,NA,NA,NA,NA,NA,1.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA04,barbexaclone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA30,metharbital,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB01,ethotoin,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB02,phenytoin,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB03,amino(diphenylhydantoin) valeric acid,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB04,mephenytoin,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB05,fosphenytoin,NA,NA,NA,NA,NA,NA,NA,NA,0.45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB52,"phenytoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB54,"mephenytoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC01,paramethadione,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC02,trimethadione,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC03,ethadione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD01,ethosuximide,NA,NA,NA,NA,NA,NA,NA,1.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD02,phensuximide,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD03,mesuximide,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD51,"ethosuximide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AE,Benzodiazepine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AE01,clonazepam,NA,NA,NA,NA,NA,NA,NA,8,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF01,carbamazepine,NA,NA,NA,NA,NA,NA,NA,1,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,g,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF02,oxcarbazepine,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF03,rufinamide,NA,NA,NA,NA,NA,NA,NA,1.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF04,eslicarbazepine,NA,NA,NA,NA,NA,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG01,valproic acid,NA,NA,NA,NA,NA,NA,NA,1.5,1.5,1.5,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG02,valpromide,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG03,aminobutyric acid,NA,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG04,vigabatrin,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG05,progabide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG06,tiagabine,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX03,sultiame,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX07,phenacemide,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX09,lamotrigine,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX10,felbamate,NA,NA,NA,NA,NA,NA,NA,2.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX11,topiramate,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX13,pheneturide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX14,levetiracetam,NA,NA,NA,NA,NA,NA,NA,1.5,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX15,zonisamide,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX17,stiripentol,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX18,lacosamide,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX19,carisbamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX21,retigabine,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX22,perampanel,NA,NA,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX23,brivaracetam,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX24,cannabidiol,NA,NA,NA,NA,NA,NA,NA,0.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX25,cenobamate,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX26,fenfluramine,NA,NA,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX27,ganaxolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX30,beclamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA01,trihexyphenidyl,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA02,biperiden,NA,NA,NA,NA,NA,NA,NA,10,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA03,metixene,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA04,procyclidine,NA,NA,NA,NA,NA,NA,NA,25,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA05,profenamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA08,dexetimide,NA,NA,NA,NA,NA,NA,NA,0.5,0.125,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA09,phenglutarimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA10,mazaticol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA11,bornaprine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA12,tropatepine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AB,Ethers chemically close to antihistamines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AB01,etanautine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AB,Ethers chemically close to antihistamines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AB02,orphenadrine (chloride),NA,NA,NA,NA,NA,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AC,Ethers of tropine or tropine derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AC01,benzatropine,NA,NA,NA,NA,NA,NA,NA,2,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AC,Ethers of tropine or tropine derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AC30,etybenzatropine,NA,NA,NA,NA,NA,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA01,levodopa,NA,NA,NA,NA,NA,NA,NA,3.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA02,levodopa and decarboxylase inhibitor,Refers to levodopa,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA03,"levodopa, decarboxylase inhibitor and COMT inhibitor",Refers to levodopa,NA,NA,NA,NA,NA,NA,0.45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA04,melevodopa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA05,melevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA06,etilevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA07,foslevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BB,Adamantane derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BB01,amantadine,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC01,bromocriptine,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC02,pergolide,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC03,dihydroergocryptine mesylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC04,ropinirole,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC05,pramipexole,hydrochloride,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC06,cabergoline,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC07,apomorphine,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC08,piribedil,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC09,rotigotine,patch,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD01,selegiline,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD02,rasagiline,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD03,safinamide,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX01,tolcapone,NA,NA,NA,NA,NA,NA,NA,0.45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX02,entacapone,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX03,budipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX04,opicapone,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04C,OTHER ANTIPARKINSON DRUGS,N04CX,Other antiparkinson drugs,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04CX01,istradefylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA01,chlorpromazine,NA,NA,NA,NA,NA,NA,NA,0.3,0.1,0.3,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA02,levomepromazine,NA,NA,NA,NA,NA,NA,NA,0.3,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA03,promazine,NA,NA,NA,NA,NA,NA,NA,0.3,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA04,acepromazine,NA,NA,NA,NA,NA,NA,NA,0.1,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA05,triflupromazine,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA06,cyamemazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA07,chlorproethazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB01,dixyrazine,NA,NA,NA,NA,NA,NA,NA,50,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB02,fluphenazine,depot,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB02,fluphenazine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB03,perphenazine,depot,NA,NA,NA,NA,NA,NA,NA,7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB03,perphenazine,NA,NA,NA,NA,NA,NA,NA,30,10,16,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB04,prochlorperazine,NA,NA,NA,NA,NA,NA,NA,0.1,50,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,g,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB05,thiopropazate,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB06,trifluoperazine,NA,NA,NA,NA,NA,NA,NA,20,8,20,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB07,acetophenazine,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB08,thioproperazine,NA,NA,NA,NA,NA,NA,NA,75,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB09,butaperazine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB10,perazine,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC01,periciazine,NA,NA,NA,NA,NA,NA,NA,50,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC02,thioridazine,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC03,mesoridazine,NA,NA,NA,NA,NA,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC04,pipotiazine,depot,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC04,pipotiazine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD01,haloperidol,depot,NA,NA,NA,NA,NA,NA,NA,3.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD01,haloperidol,NA,NA,NA,NA,NA,NA,NA,8,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD02,trifluperidol,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD03,melperone,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD04,moperone,NA,NA,NA,NA,NA,NA,NA,20,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD05,pipamperone,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD06,bromperidol,depot,NA,NA,NA,NA,NA,NA,NA,3.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD06,bromperidol,NA,NA,NA,NA,NA,NA,NA,10,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD07,benperidol,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD08,droperidol,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD09,fluanisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD10,lumateperone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE01,oxypertine,NA,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE02,molindone,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE03,sertindole,NA,NA,NA,NA,NA,NA,NA,16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE04,ziprasidone,NA,NA,NA,NA,NA,NA,NA,80,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE05,lurasidone,as hydrochloride,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF01,flupentixol,depot,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF01,flupentixol,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF02,clopenthixol,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF03,chlorprothixene,NA,NA,NA,NA,NA,NA,NA,0.3,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF04,tiotixene,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF05,zuclopenthixol,depot,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF05,zuclopenthixol,NA,NA,NA,NA,NA,NA,NA,30,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG01,fluspirilene,depot,NA,NA,NA,NA,NA,NA,NA,0.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG02,pimozide,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG03,penfluridol,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH01,loxapine,delivered dose,NA,NA,NA,NA,9.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH01,loxapine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH02,clozapine,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH03,olanzapine,depot,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH03,olanzapine,NA,NA,NA,NA,NA,NA,NA,10,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH04,quetiapine,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH05,asenapine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH06,clotiapine,NA,NA,NA,NA,NA,NA,NA,80,80,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH53,olanzapine and samidorphan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL01,sulpiride,NA,NA,NA,NA,NA,NA,NA,0.8,0.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL02,sultopride,NA,NA,NA,NA,NA,NA,NA,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL03,tiapride,NA,NA,NA,NA,NA,NA,NA,0.4,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL04,remoxipride,NA,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL05,amisulpride,NA,NA,NA,NA,NA,NA,NA,0.4,7.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL06,veralipride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL07,levosulpiride,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AN,Lithium,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD is based on the prophylaxis of mania or depression.",N05AN01,lithium,NA,NA,NA,NA,NA,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mmol,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX07,prothipendyl,NA,NA,NA,NA,NA,NA,NA,0.24,0.24,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX08,risperidone,depot,NA,NA,NA,NA,NA,NA,NA,2.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX08,risperidone,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX10,mosapramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX11,zotepine,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX12,aripiprazole,depot,NA,NA,NA,NA,NA,NA,NA,13.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX12,aripiprazole,NA,NA,NA,NA,NA,NA,NA,15,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX13,paliperidone,depot    Expressed as paliperidone,NA,NA,NA,NA,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX13,paliperidone,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX14,iloperidone,NA,NA,NA,NA,NA,NA,NA,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX15,cariprazine,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX16,brexpiprazole,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX17,pimavanserin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA01,diazepam,NA,NA,NA,NA,NA,NA,NA,10,10,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA02,chlordiazepoxide,NA,NA,NA,NA,NA,NA,NA,30,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA03,medazepam,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA04,oxazepam,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA05,potassium clorazepate,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA06,lorazepam,NA,NA,NA,NA,NA,NA,NA,2.5,2.5,NA,2.5,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,mg,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA07,adinazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA08,bromazepam,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA09,clobazam,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA10,ketazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA11,prazepam,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA12,alprazolam,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA13,halazepam,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA14,pinazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA15,camazepam,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA16,nordazepam,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA17,fludiazepam,NA,NA,NA,NA,NA,NA,NA,0.75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA18,ethyl loflazepate,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA19,etizolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA21,clotiazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA22,cloxazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA23,tofisopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA24,bentazepam,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA25,mexazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA56,"lorazepam, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB01,hydroxyzine,NA,NA,NA,NA,NA,NA,NA,75,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB02,captodiame,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB51,"hydroxyzine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC01,meprobamate,NA,NA,NA,NA,NA,NA,NA,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC03,emylcamate,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC04,mebutamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC51,"meprobamate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BD,Dibenzo-bicyclo-octadiene derivatives,The DDDs are based on the treatment of anxiety.,N05BD01,benzoctamine,NA,NA,NA,NA,NA,NA,NA,30,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BE,Azaspirodecanedione derivatives,The DDDs are based on the treatment of anxiety.,N05BE01,buspirone,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX01,mephenoxalone,NA,NA,NA,NA,NA,NA,NA,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX02,gedocarnil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX03,etifoxine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX04,fabomotizole,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX05,Lavandulae aetheroleum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA01,pentobarbital,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA02,amobarbital,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA03,butobarbital,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA04,barbital,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA05,aprobarbital,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA06,secobarbital,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA07,talbutal,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA08,vinylbital,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA09,vinbarbital,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA10,cyclobarbital,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA11,heptabarbital,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA12,reposal,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA15,methohexital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA16,hexobarbital,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA19,thiopental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA20,etallobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA21,allobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA22,proxibarbal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CB,"Barbiturates, combinations",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CB01,combinations of barbiturates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CB,"Barbiturates, combinations",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CB02,barbiturates in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC01,chloral hydrate,NA,NA,NA,NA,NA,NA,NA,1,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,g,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC02,chloralodol,NA,NA,NA,NA,NA,NA,NA,1.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC03,acetylglycinamide chloral hydrate,NA,NA,NA,NA,NA,NA,NA,1.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC04,dichloralphenazone,NA,NA,NA,NA,NA,NA,NA,1.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC05,paraldehyde,NA,NA,NA,NA,NA,NA,NA,5,5,5,NA,NA,NA,NA,NA,NA,NA,NA,g,g,g,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD01,flurazepam,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD02,nitrazepam,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD03,flunitrazepam,NA,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD04,estazolam,NA,NA,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD05,triazolam,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,mg,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD06,lormetazepam,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD07,temazepam,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD08,midazolam,NA,NA,NA,NA,NA,NA,5,15,15,NA,10,NA,NA,NA,NA,NA,NA,mg,mg,mg,NA,mg,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD09,brotizolam,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD10,quazepam,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD11,loprazolam,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD12,doxefazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD13,cinolazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD14,remimazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD15,nimetazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE01,glutethimide,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE02,methyprylon,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE03,pyrithyldione,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF01,zopiclone,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF02,zolpidem,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF03,zaleplon,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF04,eszopiclone,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH01,melatonin,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH02,ramelteon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH03,tasimelteon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ01,suvorexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ02,lemborexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ03,daridorexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM01,methaqualone,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM02,clomethiazole,NA,NA,NA,NA,NA,NA,NA,1.5,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM03,bromisoval,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM04,carbromal,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM05,scopolamine,NA,NA,NA,NA,NA,NA,NA,0.9,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM06,propiomazine,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM07,triclofos,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM08,ethchlorvynol,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM09,Valerianae radix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM10,hexapropymate,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM11,bromides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM12,apronal,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM13,valnoctamide,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM15,methylpentynol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM16,niaprazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM18,dexmedetomidine,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX01,"meprobamate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX02,"methaqualone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX03,"methylpentynol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX04,"clomethiazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX05,"emepronium, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX06,"dipiperonylaminoethanol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA01,desipramine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA02,imipramine,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA03,imipramine oxide,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA04,clomipramine,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA05,opipramol,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA06,trimipramine,NA,NA,NA,NA,NA,NA,NA,0.15,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA07,lofepramine,NA,NA,NA,NA,NA,NA,NA,0.105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA08,dibenzepin,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA09,amitriptyline,NA,NA,NA,NA,NA,NA,NA,75,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA10,nortriptyline,NA,NA,NA,NA,NA,NA,NA,75,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA11,protriptyline,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA12,doxepin,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA13,iprindole,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA14,melitracen,NA,NA,NA,NA,NA,NA,NA,75,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA15,butriptyline,NA,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA16,dosulepin,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA17,amoxapine,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA18,dimetacrine,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA19,amineptine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA21,maprotiline,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA23,quinupramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB02,zimeldine,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB03,fluoxetine,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB04,citalopram,NA,NA,NA,NA,NA,NA,NA,20,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB05,paroxetine,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB06,sertraline,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB07,alaproclate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB08,fluvoxamine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB09,etoperidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB10,escitalopram,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF01,isocarboxazid,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF02,nialamide,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF03,phenelzine,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF04,tranylcypromine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF05,iproniazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF06,iproclozide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AG,Monoamine oxidase A inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AG02,moclobemide,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AG,Monoamine oxidase A inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AG03,toloxatone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX01,oxitriptan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX02,tryptophan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX03,mianserin,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX04,nomifensine,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX05,trazodone,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX06,nefazodone,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX07,minaprine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX08,bifemelane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX09,viloxazine,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX10,oxaflozane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX11,mirtazapine,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX12,bupropion,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX13,medifoxamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX14,tianeptine,NA,NA,NA,NA,NA,NA,NA,37.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX15,pivagabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX16,venlafaxine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX17,milnacipran,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX18,reboxetine,NA,NA,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX19,gepirone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX21,duloxetine,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX22,agomelatine,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX23,desvenlafaxine,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX24,vilazodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX25,Hyperici herba,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX26,vortioxetine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX27,esketamine,NA,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX28,levomilnacipran,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX29,brexanolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX62,bupropion and dextromethorphan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA01,amfetamine,NA,NA,NA,NA,NA,NA,NA,15,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA02,dexamfetamine,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA03,metamfetamine,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA04,methylphenidate,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA05,pemoline,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA06,fencamfamin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA07,modafinil,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA08,fenozolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA09,atomoxetine,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA10,fenetylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA11,dexmethylphenidate,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA12,lisdexamfetamine,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA13,armodafinil,NA,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA14,solriamfetol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA15,dexmethylphenidate and serdexmethylphenidate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BC,Xanthine derivatives,NA,N06BC01,caffeine,NA,NA,NA,NA,NA,NA,NA,0.4,0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BC,Xanthine derivatives,NA,N06BC02,propentofylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX01,meclofenoxate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX02,pyritinol,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX03,piracetam,NA,NA,NA,NA,NA,NA,NA,2.4,6,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX04,deanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX05,fipexide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX06,citicoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX07,oxiracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX08,pirisudanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX09,linopirdine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX10,nizofenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX11,aniracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX12,acetylcarnitine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX13,idebenone,NA,NA,NA,NA,NA,NA,NA,0.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX14,prolintane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX15,pipradrol,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX16,pramiracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX17,adrafinil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX18,vinpocetine,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX21,temgicoluril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX22,phenibut,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA01,amitriptyline and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA02,melitracen and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA03,fluoxetine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CB,Psychostimulants in combination with psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA01,tacrine,NA,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA02,donepezil,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA03,rivastigmine,delivered dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA03,rivastigmine,NA,NA,NA,NA,NA,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA04,galantamine,NA,NA,NA,NA,NA,NA,NA,16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA05,ipidacrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA52,donepezil and memantine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA53,"donepezil, memantine and Ginkgo folium",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX01,memantine,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX02,Ginkgo folium,NA,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX03,aducanumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX04,lecanemab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX05,donanemab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA01,neostigmine,NA,NA,NA,NA,NA,NA,NA,60,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA02,pyridostigmine,NA,NA,NA,NA,NA,NA,NA,0.18,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA03,distigmine,NA,NA,NA,NA,NA,NA,NA,5,0.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA30,ambenonium,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA51,"neostigmine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AB,Choline esters,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AB01,carbachol,NA,NA,NA,NA,NA,NA,NA,6,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AB,Choline esters,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AB02,bethanechol,NA,NA,NA,NA,NA,NA,NA,45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX01,pilocarpine,NA,NA,NA,NA,NA,NA,NA,15,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX02,choline alfoscerate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX03,cevimeline,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA01,nicotine,NA,30,NA,60,NA,NA,30,NA,NA,NA,30,14,mg,NA,mg,NA,NA,mg,NA,NA,NA,mg,mg
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA03,varenicline,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA04,cytisinicline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB01,disulfiram,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB02,calcium carbimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB03,acamprosate,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB04,naltrexone,NA,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB05,nalmefene,NA,NA,NA,NA,NA,NA,NA,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC01,buprenorphine,NA,NA,1.6,NA,NA,NA,NA,NA,2.1,NA,8,NA,NA,mg,NA,NA,NA,NA,NA,mg,NA,mg,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC02,methadone,NA,NA,NA,NA,NA,NA,NA,25,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC03,levacetylmethadol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC04,lofexidine,NA,NA,NA,NA,NA,NA,NA,1.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC05,levomethadone,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC06,diamorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC51,"buprenorphine, combinations",Refers to buprenorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA01,betahistine,NA,NA,NA,NA,NA,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA02,cinnarizine,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA03,flunarizine,NA,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA04,acetylleucine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA52,"cinnarizine, combinations",Refers to cinnarizine,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XA,Gangliosides and ganglioside derivatives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX01,tirilazad,NA,NA,NA,NA,NA,NA,NA,NA,0.42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX02,riluzole,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX03,xaliproden,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX04,sodium oxybate,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX05,amifampridine,NA,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX06,tetrabenazine,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX07,fampridine,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX08,tafamidis,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX10,laquinimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX11,pitolisant,NA,NA,NA,NA,NA,NA,NA,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX12,patisiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX13,valbenazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX14,edaravone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX15,inotersen,NA,NA,NA,NA,NA,NA,NA,NA,41,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX16,deutetrabenazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX17,arimoclomol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX18,vutrisiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX19,sodium phenylbutyrate and ursodoxicoltaurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX21,eplontersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX22,tofersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX23,troriluzole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX59,"dextromethorphan, combinations",Refers to dextromethorphan,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA
